What is D&D Pharmatech?
D&D Pharmatech is a clinical-stage global biotechnology company dedicated to advancing medicine through a unique model of disease-specific subsidiary companies. These subsidiaries are established and guided by leading medical research faculty, ensuring a strong foundation in scientific innovation. Founded in 2014, the company operates with a presence in both Korea and the US, focusing on the development of novel therapeutics. Its strategy involves leveraging specialized expertise within each subsidiary to tackle complex diseases, positioning D&D Pharmatech as a key player in the pharmaceutical research and development landscape.
How much funding has D&D Pharmatech raised?
D&D Pharmatech has raised a total of $198.9M across 3 funding rounds:
Series B
$137.1M
Series C
$51M
Debt
$10.8M
Series B (2019): $137.1M with participation from Smilegate Investment, InterVest, LB Investment, Magna Investment, and Octave Life Sciences
Series C (2021): $51M led by Praxis Capital Partners, Kudos Venture Capital, KOREA INVESTMENT & SECURITIES, and DS Asset Management
Debt (2025): $10.8M, investors not publicly disclosed
Key Investors in D&D Pharmatech
Smilegate Investment
Smilegate Foundation operates in the Software industry, indicating a potential interest in technology-driven aspects of biotech or operational efficiency within D&D Pharmatech's business model.
LB Investment
LB Investment focuses on transformative technologies that enhance human life, particularly in deep-tech, healthcare, and digital transformation, aligning with D&D Pharmatech's mission to develop groundbreaking innovations in medicine.
Praxis Capital Partners
Praxis Capital Partners is an independent private equity firm that provides growth capital investments for domestic growth companies, suggesting a focus on scaling D&D Pharmatech's operations and market reach.
What's next for D&D Pharmatech?
The recent major strategic investment signals a pivotal phase for D&D Pharmatech, likely enabling the acceleration of its clinical pipeline and the expansion of its research capabilities. This influx of capital is expected to fuel the progression of its subsidiary companies through critical development milestones, potentially leading to new drug approvals and market entries. The company's focus on disease-specific development, backed by top-tier medical faculty, suggests a strategic approach to addressing unmet medical needs. Future growth will likely involve further strategic partnerships, continued investment in R&D, and the scaling of operations to support its expanding portfolio.
See full D&D Pharmatech company page
